Market Place
Sourcing Support
Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo®
22 May 2024 //
PRESS RELEASE
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
Xbrane provides reg update on FDA review of its ranibizumab biosimilar candidate
13 Apr 2024 //
PRESS RELEASE
Stada and Xbrane gain EU approval for biosimilar Ximluci
11 Nov 2022 //
PHARMATIMES
STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar
16 Sep 2022 //
STADA
Russia Launches Omalizumab; Remsima Sales Soar; Xbrane Trial Results
19 Feb 2022 //
CENTERFORBIOSIMILARS
Biogen and Xbrane Announce Commercialization and License Agreement for CIMZIA
07 Feb 2022 //
GLOBENEWSWIRE
Xbrane has initiated development of two new biosimilar candidates
13 Dec 2021 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.